• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Sunitinib increases disease free survival in high risk renal carcinoma post nephrectomy

byNeil D'SouzaandShaidah Deghan, MSc. MD
December 10, 2016
in Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with locoregional clear-cell renal cell carcinoma (RCC) at high risk of recurrence post nephrectomy, those taking sunitinib had a significantly longer median disease-free survival compared to those in the placebo group.

2. The rate of adverse events were greater in patients who took sunitinib compared to those taking placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The prognosis of RCC is dependent on stage. Individuals with locoregional disease (stage 3) have high rates of relapse after nephrectomy. There is currently no curative treatment for such patients, and adjuvant therapies are used to help decrease the rate of relapse. One such therapy showing proven efficacy is antiangiogenic drugs, such as the vascular endothelial growth factor (VEGF) pathway inhibitor sunitinib in patients with metastatic RCC. In this randomized, double blind, phase 3 trial, sunitinib was compared to placebo for adjuvant treatment for patients at high risk of recurrence of RCC following nephrectomy. The sunitinib group had a significantly longer median disease free survival compared to the placebo group. However, a greater rate of adverse events occurred in the sunitinib group which resulted in dose reductions, dose interruptions and discontinuations compared to the placebo group. The major strength of this trial was its double blind, randomized controlled methodology.

Click to read the study, published in NEJM

Relevant Reading: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal cell carcinoma (ECOG-ACRIN E2805); a double-blind, placebo-controlled, randmomised, phase 3 trial.

In-Depth [randomized controlled trial]: This was a randomized, double-blind, phase 3 trial involving 99 centers in 21 countries enrolled 615 patients, to receive either sunitinib (50 mg/day) or placebo. The primary endpoint was disease-free survival, and secondary endpoints were overall survival and safety.

RELATED REPORTS

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

A total of 615 patients were enrolled in the study. From these patients, 306 received sunitinib and 304 received placebo. The median disease free survival was 6.8 years (95%CI 5.8-not reached) in the sunitinib group, and 5.6 years (95%CI 3.6-6.6) in the placebo group (HR 0.75; 95%CI 0.59 – 0.98; p = 0.03). Treatment-emergent adverse events occurred in 99.7% receiving sunitinib, and 88.5% of patients receiving placebo. The most common adverse events in the sunitinib group were diarrhea, palmar-plantar erythrodysesthesia, hypertension, fatigue and nausea. Dose reductions or interruptions due to adverse events occurred in 34.3% and 46.4%, respectively, in those taking sunitinib, and 2% and 13.2% in the placebo group. Treatment discontinuations due to adverse events occurred in 86 patients (26.1%) in the sunitinib group, and 17 patients (5.6%) in the placebo group. No deaths were the result of toxic effects.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: renal-cell carcinoma
Previous Post

Correlations among evaluation systems of US internal medicine residents

Next Post

A scoping review of primary care-based models for medication-assisted treatment of opioid use disorder

RelatedReports

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients
StudyGraphics

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

October 13, 2021
Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Nephrology

Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

October 4, 2021
#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence
StudyGraphics

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

April 20, 2021
Pediatric renal and thyroid cancer rates increase
Nephrology

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

April 12, 2021
Next Post
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

A scoping review of primary care-based models for medication-assisted treatment of opioid use disorder

Increasing maternal BMI linked to higher risk of cerebral palsy

Fluctuating Weight-for-Length Trends in Infants from 2000 to 2014

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

Post-myocardial infarction beta-blockers improve mortality but may decrease function in elderly nursing home patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities
  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.